

Revision date: 28-Jul-2011

Version: 1.1

Page 1 of 12

#### **IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING** 1.

**Pfizer Animal Health** Pfizer Inc 235 East 42nd Street New York, NY 10017 Poison Control Center Phone: 1-866-531-8896 Technical Services Phone: 1-800-366-5288 Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ** United Kingdom +00 44 (0)1304 616161 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

# Material Name: VMP Tablets

Trade Name:	VMP Tablets
Synonyms:	Vitamin, Mineral, Protein Tablets
Chemical Family:	Mixture
Intended Use:	Veterinary product used as dietary supplement

# 2. HAZARDS IDENTIFICATION

Appearance:	Tablets
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term: EU Classification EU Indication of danger:	May be harmful if swallowed. May be harmful if absorbed through the skin. (based on components) Not classified

Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

# **3. COMPOSITION/INFORMATION ON INGREDIENTS**

Hazardous				
Ingredient	CAS Number	EU EINECS/ELINCS List	<b>EU Classification</b>	%

#### Material Name: VMP Tablets Revision date: 28-Jul-2011

3. COMPOSITION/INFORMATION C	ON INGREDIENTS			
AMORPHOUS SILICA	7631-86-9	231-545-4	Not Listed	*
		418-260-2		
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	Not Listed	*
Cholecalciferol (Vitamin D3)	67-97-0	200-673-2	T+;R26	<0.1
			T;R24/25	
			T;R48/25	
Cyanocobalamin (Vitamin B12)	68-19-9	200-680-0	Not Listed	*
Iron oxide	1309-37-1	215-168-2	Not Listed	*
Magnesium oxide	1309-48-4	215-171-9	Not Listed	*
Manganese carbonate	17375-37-0	241-414-3	Not Listed	*
Riboflavin (Vitamin B2)	83-88-5	201-507-1	Not Listed	*
Zinc oxide	1314-13-2	215-222-5	N;R50/53	<0.25

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Biotin	58-85-5	200-399-3	Not Listed	*
Butylated hydroxyanisole	25013-16-5	246-563-8	Not Listed	*
Copper sulfate, anhydrous	7758-98-7	231-847-6	Not Listed	*
Flavor	NOT ASSIGNED	Not Listed	Not Listed	*
Folic Acid	59-30-3	200-419-0	Not Listed	*
Lecithin	8002-43-5	232-307-2	Not Listed	*
Niacinamide	98-92-0	202-713-4	Not Listed	*
Peanut Oil	8002-03-7	232-296-4	Not Listed	*
Pyridoxine Hydrochloride (Vitamin B6)	58-56-0	200-386-2	Not Listed	*
Taurine	107-35-7	203-483-8	Not Listed	*
Thiamine Mononitrate	532-43-4	208-537-4	Not Listed	*
Vitamin A Acetate	127-47-9	204-844-2	Not Listed	*
Vitamin E (D-alpha-Tocopherol)	59-02-9	200-412-2	Not Listed	*
Yeast, extract	8013-01-2	232-387-9	Not Listed	*
Lactose Monohydrate	64044-51-5	Not Listed	Not Listed	*

**Additional Information:** 

#### \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

#### For the full text of the R phrases mentioned in this Section, see Section 16

Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Extinguishing Media:** 

Use carbon dioxide, dry chemical, or water spray.

Material Name: VMP Tablets Revision date: 28-Jul-2011	Page 3 of 12 Version: 1.1
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Not applicable
6. ACCIDENTAL RELEASE ME	EASURES
Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.Measures for Environmental<br/>Protections:Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to<br/>avoid environmental release.Additional Consideration for Large<br/>Spills:Non-essential personnel should be evacuated from affected area. Report emergency<br/>situations immediately. Clean up operations should only be undertaken by trained personnel.

# 7. HANDLING AND STORAGE

General Handling:	Avoid breathing dust, vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process
Storage Conditions:	emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Store as directed by product packaging.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

AMORPHOUS SILICA	
Australia TWA	2 mg/m <sup>3</sup>
Austria OEL - MAKs	4 mg/m <sup>3</sup>
Czech Republic OEL - TWA	0.1 mg/m <sup>3</sup>
	4.0 mg/m <sup>3</sup>
Estonia OEL - TWA	2 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	4 mg/m <sup>3</sup>
Germany (DFG) - MAK	4 mg/m <sup>3</sup> inhalable fraction
Ireland OEL - TWAs	6 mg/m <sup>3</sup>
	2.4 mg/m <sup>3</sup>
Latvia OEL - TWA	1 mg/m <sup>3</sup>
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m <sup>3</sup>
Slovenia OEL - TWA	4 mg/m <sup>3</sup>
Calcium phosphate dibasic, anhydrous	
Latvia OEL - TWA	10 mg/m <sup>3</sup>

opper sulfate, anhydrous	
ACGIH Threshold Limit Value (TWA)	1 mg/m <sup>3</sup>
Finland OEL - TWA	1 mg/m <sup>3</sup>
	, mg/m
on oxide	
ACGIH Threshold Limit Value (TWA)	5 mg/m <sup>3</sup>
Australia TWA	5 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Belgium OEL - TWA	2 ppm
•	5 mg/m <sup>3</sup>
Denmark OEL - TWA	3.5 mg/m <sup>3</sup>
Estonia OEL - TWA	3.5 mg/m <sup>3</sup>
Finland OEL - TWA	5 mg/m <sup>3</sup>
France OEL - TWA	5 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
Hungary OEL - TWA	6 mg/m <sup>3</sup>
Ireland OEL - TWAs	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Lithuania OEL - TWA	3.5 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	10 mg/m <sup>3</sup>
Poland OEL - TWA	5 mg/m <sup>3</sup>
Portugal OEL - TWA	5 mg/m <sup>3</sup>
Romania OEL - TWA	5 mg/m <sup>3</sup>
Slovakia OEL - TWA	1.5 mg/m <sup>3</sup>
Spain OEL - TWA	5 mg/m <sup>3</sup>
Sweden OEL - TWAs	$3.5 \text{ mg/m}^3$
agnesium oxide	
ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	5 mg/m <sup>3</sup>
Denmark OEL - TWA	6 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Germany (DFG) - MAK	1.5 mg/m <sup>3</sup> respirable fraction
	4 mg/m <sup>3</sup> inhalable fraction
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Hungary OEL - TWA	6 mg/m <sup>3</sup>
Ireland OEL - TWAs	4 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	4 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	15 mg/m³
Poland OEL - TWA	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>

Romania OEL - TWA	5 mg/m <sup>3</sup>
Slovakia OEL - TWA	1.5 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
iacinamide	
Latvia OEL - TWA	1 mg/m <sup>3</sup>
Lithuania OEL - TWA	1 mg/m <sup>3</sup>
iboflavin (Vitamin B2)	
Latvia OEL - TWA	1 mg/m <sup>3</sup>
Lithuania OEL - TWA	1 mg/m <sup>3</sup>
inc oxide	
ACGIH Threshold Limit Value (TWA)	2 mg/m <sup>3</sup>
ACGIH Threshold Limit Value (STEL)	10 mg/m <sup>3</sup>
Australia STEL	10 mg/m <sup>3</sup>
Australia TWA	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
-	5 mg/m <sup>3</sup>
Bulgaria OEL - TWA	5.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	2 mg/m <sup>3</sup>
Denmark OEL - TWA	4 mg/m <sup>3</sup>
Estonia OEL - TWA	5 mg/m <sup>3</sup>
Finland OEL - TWA	2 mg/m <sup>3</sup>
France OEL - TWA	5 mg/m³
	10 mg/m <sup>3</sup>
Germany (DFG) - MAK	1 mg/m <sup>3</sup> fume, respirable fraction
Greece OEL - TWA	5 mg/m <sup>3</sup>
Hungary OEL - TWA	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	5 mg/m <sup>3</sup>
Latvia OEL - TWA	0.5 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	5 mg/m <sup>3</sup>
	15 mg/m <sup>3</sup>
Poland OEL - TWA	5 mg/m <sup>3</sup>
Portugal OEL - TWA	2 mg/m <sup>3</sup>
Romania OEL - TWA	5 mg/m <sup>3</sup>
Slovakia OEL - TWA	1 mg/m <sup>3</sup>
Slovenia OEL - TWA	5 mg/m <sup>3</sup>
Spain OEL - TWA	5 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>
holecalciferol (Vitamin D3)	
Pfizer Occupational Exposure OEB 5 (cont Band (OEB):	trol exposure to <1ug/m <sup>3</sup> )
olic Acid	
	trol exposure to the range of >10ug/m <sup>3</sup> to < 100ug/m <sup>3</sup> )

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Environmental Exposure Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. Refer to specific Member State legislation for requirements under Community environmental legislation.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY		
Chemical Stability: Conditions to Avoid: Incompatible Materials:	Stable under normal conditions of use. Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers	

#### **11. TOXICOLOGICAL INFORMATION**

General Information:

The information in this section describes the potential hazards of the individual ingredients and the formulation.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Thiamine Mononitrate**

Mouse Oral LD50 > 5000 mg/kg

Lecithin Rat Oral LD50 > 8 ml/kg

#### Cholecalciferol (Vitamin D3) Rat Oral LD50 42 mg/kg

Mouse Sub-tenon injection (eye) LD 50 136 mg/kg

Folic Acid

Mouse Oral LD 50 10 g/kg

# **11. TOXICOLOGICAL INFORMATION**

#### Pyridoxine Hydrochloride (Vitamin B6)

Rat Oral LD 50 4 g/kg

#### Niacinamide

Oral LD50 Rat 3500 mg/kg Mouse Oral LD50 2500 mg/kg 1680 g/kg Rat Subcutaneous LD50 IP Mouse LD50 2050 mg/kg Rabbit >2000 mg/kg Dermal LD 50

#### Vitamin E (D-alpha-Tocopherol)

Mouse Oral LD 50 >25 mL/kg

#### Vitamin A Acetate

Mouse Oral LD 50 4100 mg/kg

#### Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

#### **Butylated hydroxyanisole**

Rat Oral LD50 2000 mg/kg Mouse Oral LD 50 1100 mg/kg Rat Intraperitoneal LD 50 881 mg/kg

#### Zinc oxide

Mouse Oral LD50 7950 mg/kg IP LD50 240 mg/kg Rat Mouse Inhalation LD50 2500 mg/m<sup>3</sup> Oral LD 50 Rat >5000 mg/kg A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable **Acute Toxicity Comments:** at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

Peanut Oil Skin Irritation Rabbit Moderate

#### Zinc oxide

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

#### **Butylated hydroxyanisole**

12 Day(s) Rat Oral 3300 mg/kg LOAEL Liver, Blood

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Cholecalciferol (Vitamin D3) Embryo / Fetal Development	Rat	Subcuta	aneous	90 mg/k	g/day	LOEL	Teratogenic	
Butylated hydroxyanisole Embryo / Fetal Development	Rat	Oral	30 g/kg	LOEL	Terat	ogenic		

PZ01401

#### Material Name: VMP Tablets Revision date: 28-Jul-2011

#### **11. TOXICOLOGICAL INFORMATION** Genetic Toxicity: (Study Type, Cell Type/Organism, Result) **Cholecalciferol (Vitamin D3)** In Vitro Bacterial Mutagenicity (Ames) Negative Salmonella Lactose Monohydrate In Vitro Bacterial Mutagenicity (Ames) Negative Peanut Oil Bacterial Mutagenicity (Ames) Salmonella Negative **Butylated hydroxyanisole** In Vivo Micronucleus Bone Marrow Negative In Vitro Bacterial Mutagenicity (Ames) Salmonella Negative **Butylated hydroxyanisole** Two Year(s) Rat Oral 728 g/kg/day Gastrointestinal system, Tumors Two Year(s) Rat Oral 874 g/kg/day Gastrointestinal system, Endocrine system, Tumors None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. **Carcinogen Status: AMORPHOUS SILICA** Group 3 (Not Classifiable) IARC: Iron oxide Group 3 (Not Classifiable) IARC: **Butylated hydroxyanisole** Group 2B (Possibly Carcinogenic to Humans) IARC: NTP: Reasonably Anticipated To Be A Human Carcinogen

12. ECOLOGICAL INFORMATION		
Environmental Overview:	The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.	

# Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Zinc oxide Tadpole EC50 48 Hours 3.2 mg/L

# **13. DISPOSAL CONSIDERATIONS**

# Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State<br/>specific and Community specific provisions must be considered. Considering the relevant<br/>known environmental and human health hazards of the material, review and implement<br/>appropriate technical and procedural waste water and waste disposal measures to prevent<br/>occupational exposure and environmental release. It is recommended that waste minimization<br/>be practiced. The best available technology should be utilized to prevent environmental<br/>releases. This may include destructive techniques for waste and wastewater.

# **14. TRANSPORT INFORMATION**

#### The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

EU Indication of danger: Not classified

# OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

#### **Canada - WHMIS: Classifications**

#### WHMIS hazard class:

None required This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

AMORPHOUS SILICA Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 231-545-4 418-260-2
Biotin	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-399-3
Butylated hydroxyanisole	
California Proposition 65	carcinogen initial date 1/1/90
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	246-563-8
Calcium phosphate dibasic, anhydrous	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-826-1
Cholecalciferol (Vitamin D3)	
Inventory - United States TSCA - Sect. 8(b)	Present

## Material Name: VMP Tablets Revision date: 28-Jul-2011

15. REGULATORY INFORMATION	Procent
Australia (AICS): Standard for the Uniform Scheduling	Present Schedule 7
Standard for the Uniform Scheduling for Drugs and Poisons:	
EU EINECS/ELINCS List	200-673-2
Copper sulfate, anhydrous	
CERCLA/SARA Hazardous Substances	10 lb
and their Reportable Quantities:	4.54 kg
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 6
for Drugs and Poisons:	004.047.0
EU EINECS/ELINCS List	231-847-6
Cyanocobalamin (Vitamin B12)	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-680-0
Folic Acid	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present Schodula 2
Standard for the Uniform Scheduling	Schedule 2
for Drugs and Poisons: EU EINECS/ELINCS List	Schedule 4 200-419-0
EU EINEUJ/ELINUJ LISI	200-413-0
Iron oxide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-168-2
Lecithin	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	232-307-2
Magnesium oxide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-171-9
Manganese carbonate	
EU EINECS/ELINCS List	241-414-3
Niacinamide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-713-4
Peanut Oil	
Inventory - United States TSCA - Sect. 8(b)	Present

# Material Name: VMP Tablets Revision date: 28-Jul-2011

15. REGULATORY INFORMATION	-
Australia (AICS):	Present
EU EINECS/ELINCS List	232-296-4
Pyridoxine Hydrochloride (Vitamin B6)	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-386-2
Riboflavin (Vitamin B2)	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-507-1
	201-307-1
Taurine	Descent
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-483-8
Thiamine Mononitrate	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	208-537-4
Vitamin A Acetate	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-844-2
Vitamin E (D-alpha-Tocopherol) Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-412-2
Yeast, extract Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-387-9
EU EINEUJ/ELINUJ LIST	252-501-9
Zinc oxide	5
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-222-5
Lactose Monohydrate	
Australia (AICS):	Present

# **16. OTHER INFORMATION**

# Text of R phrases mentioned in Section 3

R26 - Very toxic by inhalation.

Material Name:	VMP Tablets
Revision date: 2	28-Jul-2011

 R24/25 - Toxic in contact with skin and if swallowed.

 R48/25 - Toxic: danger of serious damage to health by prolonged exposure if swallowed.

 R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

 Data Sources:
 Publicly available toxicity information. Safety data sheets for individual ingredients.

 Reasons for Revision:
 Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by:

Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet